An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
NCT06693336
Recruiting
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/20/2024
Locations: Toronto General Hospital, Toronto, Ontario
Conditions: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Register for Updates
Mucopolysaccharidosis I (MPS I) Registry
NCT00144794
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the lon... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Phoenix Children's Hospital- Site Number : 840003, Phoenix, Arizona +179 locations
Conditions: Mucopolysaccharidosis I (MPS I)
Register for Updates
Fecal Microbiota Transplantation for Pouchitis
NCT03545386
Recruiting
This is a randomized double-blind placebo controlled trial involving a single centre (McMaster University) recruiting patients from Hamilton, ON and the surrounding regions, to evaluate whether fecal microbiota transplantation once weekly for six weeks increases the remission rate compared to placebo in patients with active pouchitis.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/19/2024
Locations: McMaster University, Hamilton, Ontario
Conditions: Pouchitis
Register for Updates
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
NCT04002479
Recruiting
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec +1 locations
Conditions: Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
Register for Updates
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399
Recruiting
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Gender:
ALL
Ages:
30 days and above
Trial Updated:
11/19/2024
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +56 locations
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Register for Updates
Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis
NCT04792281
Recruiting
The proposed study is a multicentric prospective observational cohort study of patients with suspected NVE. The study population includes those with Possible IE according to the modified Duke criteria and investigated at one of the 6 participating sites which include 2 cardiac centers, the MHI and the IUCPQ, as well as 4 tertiary care centers, the Jewish General Hospital , the McGill University Health Centre and the CHUS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Jewish General Hospital, Montreal, Quebec +5 locations
Conditions: Infective Endocarditis, Native Valve Endocarditis
Register for Updates
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
Recruiting
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Alaska Women's Cancer Care, Anchorage, Alaska +51 locations
Conditions: Uterine Serous Carcinoma
Register for Updates
Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anterior Shoulder Dislocation ePisode
NCT04887337
Recruiting
Each year within Canada and the US, more than 30,000 children and adolescents will have an injury to their shoulder resulting in a shoulder dislocation. Although the current practice is to manage this initial dislocation without surgery, the vast majority of these children and adolescents will, unfortunately continue to have instability episodes of their shoulder. Recurrent instability can cause damage to the bones and cartilage that form the shoulder resulting in potentially more difficult surg... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
11/19/2024
Locations: McMaster University, Hamilton, Ontario
Conditions: Shoulder Dislocation
Register for Updates
Sputum-guided Treatment With Comprehensive Care Management in COPD - A Randomized-controlled Trial
NCT04890938
Recruiting
Chronic obstructive pulmonary disease (COPD) is a lung condition affecting 1 in 6 Canadians and does not have a cure. Flare-ups of COPD are the most common reason someone goes to hospital in Canada. This is made worse because within 30-days of having a flare-up, 1 in 5 patients will come back to hospital for the same problem. Flare-ups of COPD often have many causes and these are different person to person. Sometimes it is related to behaviours such as smoking or not using medicines properly. O... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
11/19/2024
Locations: Hamilton General Hospital, Hamilton, Ontario +1 locations
Conditions: COPD
Register for Updates
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811
Recruiting
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Beverly Hills Cancer Center, Beverly Hills, California +72 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212
Recruiting
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This s... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/19/2024
Locations: St. Vincent's Birmingham (Pharmacy), Birmingham, Alabama +327 locations
Conditions: Lower Respiratory Tract Illness
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +30 locations
Conditions: Myocarditis Acute, Cancer
Register for Updates